Related Experiment Video
Updated: Feb 16, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Tacrolimus - Pharmacokinetic Considerations for Clinicians.
Katharina Schutte-Nutgen1, Gerold Tholking1, Barbara Suwelack1
1Department of Medicine D, University of Munster, Munster, Germany.
Tacrolimus (Tac) blood concentration normalized by dose (C/D ratio) helps classify patients post-transplant. This C/D ratio is linked to patient outcomes, aiding in managing immunosuppressive therapy.
Area of Science:
- Pharmacology
- Transplantation Medicine
- Clinical Chemistry
Background:
- Tacrolimus (Tac) is a key immunosuppressant after renal transplantation (RTx).
- Managing Tac therapy is complex due to its narrow therapeutic window and variable metabolism.
- Therapeutic drug monitoring is essential for dose adjustment.
Purpose of the Study:
- To classify patients based on Tac metabolism using the C/D ratio.
- To investigate the association between the C/D ratio and transplant outcomes.
Main Methods:
- Calculation of the C/D ratio (blood concentration normalized by dose).
- Classification of patients into two major Tac metabolism groups.
- Statistical analysis of C/D ratio association with transplant outcomes.
Main Results:
- Patients receiving Tac can be categorized into two main metabolism groups based on the C/D ratio.
- The C/D ratio significantly correlates with renal outcomes in kidney and liver transplant recipients.
Conclusions:
- The C/D ratio is a valuable tool for understanding Tac metabolism and predicting transplant outcomes.
- Findings are relevant for transplant physicians managing immunosuppressive therapy.
- Review covers Tac pharmacokinetics, genetics, formulations, and clinical implications.
Related Concept Videos
Design Consideration
The factor of safety is another key...
Tensile Strength Considerations of Concrete
The dimensions and shape of a concrete specimen...
Transmission Line Design Considerations
Special considerations while measuring pulse
Energy Considerations in Open Channel Flow
Pharmacokinetics: Overview

